Q2 EPS Estimates for AstraZeneca Boosted by Zacks Research

AstraZeneca PLC (NASDAQ:AZN) – Zacks Research raised their Q2 2026 earnings per share estimates for AstraZeneca in a research note issued on Tuesday, May 20th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.21 for the quarter, up from their prior estimate of $1.19. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share. Zacks Research also issued estimates for AstraZeneca’s Q3 2026 earnings at $1.28 EPS and FY2026 earnings at $4.95 EPS.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter last year, the business posted $2.06 EPS. AstraZeneca’s quarterly revenue was up 7.2% compared to the same quarter last year.

Other research analysts have also issued reports about the stock. Morgan Stanley started coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an “overweight” rating for the company. BNP Paribas initiated coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price on the stock. Finally, UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $88.00.

AstraZeneca Stock Performance

AstraZeneca stock opened at $70.41 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. AstraZeneca has a 12 month low of $61.24 and a 12 month high of $87.68. The company has a fifty day moving average price of $69.77 and a two-hundred day moving average price of $69.45. The company has a market cap of $218.36 billion, a PE ratio of 31.16, a P/E/G ratio of 1.42 and a beta of 0.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. raised its stake in AstraZeneca by 11.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 17,968 shares of the company’s stock valued at $1,321,000 after acquiring an additional 1,910 shares in the last quarter. Focus Partners Wealth raised its stake in shares of AstraZeneca by 15.3% during the first quarter. Focus Partners Wealth now owns 79,640 shares of the company’s stock valued at $5,854,000 after purchasing an additional 10,573 shares in the last quarter. Integrity Alliance LLC. acquired a new stake in AstraZeneca in the first quarter worth about $440,000. SCS Capital Management LLC acquired a new stake in AstraZeneca in the first quarter worth about $3,066,000. Finally, Exome Asset Management LLC bought a new position in AstraZeneca in the 1st quarter valued at about $2,391,000. Institutional investors own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.